's () Alexis Abraham talks to Proactive London's Katie Pilbeam about their first day of trading on the London Stock Exchange.
Abraham says he is 'delighted the UK has embraced cannabinoids and our listing with such enthusiasm'.
The provider of premium consumer products based on biosynthetic cannabinoids, which are compounds produced in the lab from cannabis plants, completed its initial public offering (IPO) after a £13mln fundraising.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE